期刊
DRUGS OF TODAY
卷 52, 期 3, 页码 173-181出版社
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dot.2016.52.3.2463564
关键词
Idebenone; LHON; Inherited mitochondrial respiratory chain diseases; Metabolic diseases; Leber's hereditary optic neuropathy; Genetic disorders
Idebenone is a rapidly absorbed, safe and well-tolerated drug and is currently the only clinically proven treatment option for Leber's hereditary optic neuropathy (LHON) patients. Idebenone (Raxone (R)) is approved by the European Medicines Agency for the treatment of LHON and has been available on the European market since 2015. Due to its molecular mode of action of bypassing the defective mitochondrial complex I, idebenone leads to improved energy supply and a functional recovery of retinal ganglion cells during the acute stage of the disease, thereby preventing further vision loss and promoting recovery of vision. Thus, commencing treatment shortly after the onset of symptoms is likely to have the best therapeutic effect, a hypothesis that is supported by the available clinical data.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据